ADMA

ADMA Biologics Inc. is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of plasma-derived biologics for the treatment and prevention of infectious diseases. Headquartered in Boca Raton, Florida, the company operates an FDA-licensed plasma fractionation facility in Boca Raton and manages FDA-certified plasma collection centers across the United States. ADMA's primary commercial products include ASCENIV (immune globulin intravenous), BIVIGAM (immune globulin intravenous), and Nabi-HB (hepatitis B immune globulin), which address immune deficiency disorders and provide hepatitis B prophylaxis. The company follows a vertically integrated business model, controlling the entire value chain from plasma collection through final product manufacturing and distribution. ADMA focuses on high-value specialty plasma products derived from immune plasma, which contains elevated levels of antibodies against specific pathogens. In recent years, the company has expanded its plasma collection network to secure critical raw material supply and increased manufacturing capacity to meet growing demand for immunoglobulin therapies. ADMA serves a concentrated market of patients with primary immune deficiency disease and other antibody deficiencies requiring regular immunoglobulin replacement therapy. The company competes in the specialized immunoglobulin segment of the broader plasma protein therapeutics market, positioning itself as a domestic source of plasma-derived products at a time of increasing global demand.